However, despite its ability to induce a strong pro-angiogenic phenotype in vitro and in vivo PAD models, none of the VEGF-A clinical trials or NO supplementation by L-arginine showed any clinical benefit in PAD [4,5,6,7]. This evidence concerns the gene VEGFA and peripheral arterial disease.